Summit Creek Advisors LLC Buys New Stake in LeMaitre Vascular, Inc. $LMAT

Key Points

• Summit Creek Advisors acquired 49,174 shares of LeMaitre Vascular worth approximately $4.7 million, representing about 0.22% of the company. Hedge funds and institutional investors collectively own 84.64% of LMAT.
• LeMaitre Vascular reported quarterly revenue of $70.38 million, up 9.6% year over year, but earnings per share of $0.74 fell short of the $0.81 consensus estimate. The stock opened at $81.52, near its one-year low of $78.65.
• The company declared a quarterly dividend of $0.25 per share, equal to a 1.2% annualized yield. Analysts hold a consensus “Hold” rating with an average price target of $110.60.

Summit Creek Advisors LLC purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund purchased 49,174 shares of the medical instruments supplier's stock, valued at approximately $4,719,000. Summit Creek Advisors LLC owned about 0.22% of LeMaitre Vascular as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Sound Income Strategies LLC grew its position in shares of LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the first quarter worth about $32,000. Geneos Wealth Management Inc. boosted its stake in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after buying an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular during the second quarter valued at approximately $47,000. Finally, Quarry LP grew its holdings in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock valued at $64,000 after buying an additional 529 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $81.52 on Wednesday. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 28.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.53. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The stock has a 50 day moving average price of $94.95 and a 200-day moving average price of $99.72. LeMaitre Vascular, Inc. has a one year low of $78.65 and a one year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The company had revenue of $70.38 million for the quarter, compared to analysts' expectations of $71.47 million. During the same quarter in the previous year, the company posted $0.60 EPS. The business's quarterly revenue was up 9.6% on a year-over-year basis. Equities analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. LeMaitre Vascular's dividend payout ratio is currently 35.09%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Wall Street Zen lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Citigroup restated a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Citizens Jmp boosted their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a "market outperform" rating in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company decreased their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Hold" and an average price target of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source